Navigation Links
Regeneron Reports Third Quarter 2009 Financial and Operating Results
Date:11/3/2009

symptoms in adults and children aged 12 years and older.

ARCALYST is in a Phase 3 clinical development program for the treatment of gout. The program includes four clinical trials, all of which are currently enrolling patients. Two Phase 3 clinical trials (called PRE-SURGE 1 and PRE-SURGE 2) are evaluating ARCALYST versus placebo for the prevention of gout flares in patients initiating urate-lowering drug therapy. A third Phase 3 trial in acute gout (SURGE) is evaluating treatment with ARCALYST alone versus ARCALYST in combination with a non-steroidal anti-inflammatory drug (NSAID) versus an NSAID alone. The fourth Phase 3 trial is a placebo-controlled safety study (RE-SURGE). The Company expects to report initial data from the Phase 3 program in the first half of 2010. Regeneron owns worldwide rights to ARCALYST (rilonacept).

Aflibercept (VEGF Trap) - Oncology

Aflibercept, an anti-angiogenic protein product candidate designed to bind all forms of vascular endothelial growth factor A (VEGF-A), is being developed worldwide by Regeneron and its collaborator, sanofi-aventis. At the end of the third quarter of 2009, more than 80 percent of the planned number of patients were enrolled in each of three Phase 3 trials that are evaluating combinations of aflibercept with standard chemotherapy regimens for the treatment of cancer. One trial (called VELOUR) is evaluating aflibercept as a 2nd line treatment for metastatic colorectal cancer in combination with FOLFIRI (folinic acid (leucovorin), 5-fluorouracil, and irinotecan). A second trial (VITAL) is evaluating aflibercept as a 2nd line treatment for metastatic non-small cell lung cancer in combination with docetaxel. The third trial (VENICE) is evaluating aflibercept as a 1st line treatment for metastatic androgen-independent prostate cancer in combination with docetaxel/prednisone. All three trials are studying the current standard of chemotherapy care for the cancer bei
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Fla. , Dec. 19, 2014 Breckenridge ... a multi-product agreement with MSN Laboratories Pvt. Ltd. ( ... MSN expect to commercialize several new ANDAs.  Under the ... supply the products exclusively to Breckenridge for the U.S. ... under its label.  Breckenridge and MSN have agreed to ...
(Date:12/19/2014)... , Dec. 19, 2014  Monarch America Inc. (OTCQB: ... Corp.) is pleased to provide this review of the ... in 2015. "Over this past year, we ... I am extremely proud to say that Monarch America ... than it has ever been," stated Eric Hagen ...
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research ... announced the addition of the "Micro Market ... report to their offering. ... dermatological treatment is progressing steadily, which has resulted ... diagnostic devices market. The main purpose of these ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3
... 2007 - Geron,Corporation (Nasdaq:GERN) today announced the ... company's human,embryonic stem cell (hESC)-based therapeutic for ... direct attack by the human immune,system., Presented ... Federation of,Clinical Immunology Societies meeting in San ...
... BETHESDA, Md., June 11, 2007--New research supported ... of Arthritis and,Musculoskeletal and Skin Diseases (NIAMS) ... which is used for certain,types of seizures, ... pain and,other symptoms associated with the common, ...
Cached Medicine Technology:Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 2Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 3Gabapentin Shown Effective for Fibromyalgia Pain 2Gabapentin Shown Effective for Fibromyalgia Pain 3
(Date:12/20/2014)... holidays can be anything but joyous for people with ... and other allergy triggers. "The dust from the ... away in dank basements or dusty attics is triggering ... Shah, an affiliate faculty member at Loyola University Chicago ... Shah, who is also an allergist at Gottlieb ...
(Date:12/20/2014)... The Doctor’s Office Urgent Care of Paramus, New Jersey has ... They’ve treated over 40,000 patients while carrying out their ... to the Paramus area. , For 2015, the practice ... of top-notch board certified physicians: Christine Milosis MD, Sandra Ugras ... doctors will work tirelessly to carry out The Doctor’s ...
(Date:12/20/2014)... 2014 As Risperdal lawsuits ( ... U.S. courts, Bernstein Liebhard LLP notes the publication ... treated with the medication may experience elevated levels ... and lactation. The study, which appears in International ... who began treatment with risperidone, an antipsychotic medication ...
(Date:12/20/2014)... 20, 2014 The aftermath of the November ... stir, not only in Hollywood, but worldwide. As ... the ripples of that attack are starting a finger-pointing game ... risk. But they are not the only ones affected, ... in for some embarrassing times ahead, agents and lawyers could ...
(Date:12/20/2014)... Aliso Viejo, California (PRWEB) December 20, 2014 ... have announced the release of a new plugin for ... Pixel Film Studios. , “TranSlice Volume 5 allows users ... literally hand draw it.” Said Christina Austin, CEO of ... to add level of professionalism while maintaining an easy ...
Breaking Medicine News(10 mins):Health News:Holiday Trimmings Can Trigger Allergies 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... researchers have identified an unexpected molecular marker that ... to chemotherapy. Triple-negative breast cancers --which do ... progesterone receptor and do not have Her2/neu overexpression ... of the disease and cannot be treated with ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... early stage prostate cancer, those who have the prostate gland ... a "watchful waiting" approach, according to a new long-term study ... to be practice-changing, said Dr. Richard E. Greenberg, chief of ...
... Gardner HealthDay Reporter , WEDNESDAY, May 4 ... was able to rectify ventricular fibrillation, a severely abnormal ... none experienced sudden death, according to new research. ... is already approved in Europe and is undergoing review ...
... May issue of the journal Health Affairs , Mount ... of toxic chemicals and air pollutants in the environment, and ... also those already on the market. Leonardo Trasande, ... Sinai School of Medicine, analyzed the costs of conditions ...
... MOINES, Iowa, May 4, 2011 The Donald Danforth Plant ... from the Howard G. Buffett Foundation to bring healthier sorghum ... help fund the completion of the development of biofortified sorghum, ... upon sorghum as their staple diet. DuPont business Pioneer ...
... Translational Genomics Research Institute (TGen) has licensed its first ... modifying the actions of proteins. Today,s announcement is ... laboratory discoveries more rapidly into therapeutics that can immediately ... drug, ONCO-101, is being licensed to Syracuse, N.Y.-based Oncoholdings ...
Cached Medicine News:Health News:Gene expression predicts chemotherapy sensitivity of triple-negative breast cancer 2Health News:Aggressive Treatment May Be Beneficial for Early Prostate Cancer 2Health News:Aggressive Treatment May Be Beneficial for Early Prostate Cancer 3Health News:New Defibrillator Shows Promise in Small Study 2Health News:Estimated costs of environmental disease in children at $76.6 billion per year 2Health News:Estimated costs of environmental disease in children at $76.6 billion per year 3Health News:Grant funds next phase in bringing healthier sorghum closer to underserved communities 2Health News:TGen licenses first drug for patient use in clinical care 2
Inquire...
... incubators,Two refrigerated incubators that are ... life cycle,testing. Microprocessor controlled heating ... display. High/low audible and visual ... internal chamber safety thermostat,provides over-temperature ...
Inquire...
Inquire...
Medicine Products: